THE ENIGMATIC PROFILE: UNRAVELING CLINICAL AND BIOLOGICAL FEATURES IN COVID-19 PATIENTS

Authors

  • Irina Mihaela ESANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Oana Irina GAVRIL “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Madalina Ioana ZOTA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • A. DRUGESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Codrina ANCUTA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ionela GROSU-CREANGA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R.S. GAVRIL “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

The outbreak of COVID-19, caused by the novel coronavirus SARS-CoV-2, has emerged as an unparalleled global health crisis, affecting millions of lives worldwide. This respiratory illness exhibits a wide spectrum of clinical presentations, ranging from mild flu-like symptoms to severe acute respiratory distress syndrome (ARDS), leading to high morbidity and mortality rates, especially among vulnerable populations. In this abstract, we provide a concise overview of the clinical and biological characteristics observed in COVID-19 patients. The aim of this study was to evaluate patients with COVID-19 presenting with mild to moderate clinical and paraclinical features and their subsequent outcomes. Materials and methods: The study group included 200 patients diagnosed with confirmed COVID-19, exhibiting mild to moderate symptoms, who were admitted for treatment and health monitoring. Results: The estimated risk of SARS-CoV-2 infection was over 5 times higher in asymptomatic afebrile patients (RR=5.82; 95% CI: 0.88-38.65; p=0.004). Among asymptomatic patients, C-reactive protein (CRP) levels ranged from 0.58 to 39.88 mg/dL, while in symptomatic patients, the range varied from 0.20 to 200.17 mg/dL. The mean level of CRP was significantly higher in symptomatic patients (13.67 vs. 5.73 mg/dL; p=0.001). Regarding imaging examinations, 38.6% of subjects did not show pathological aspects. The time to viral clearance ranged from 9 to 41 days in asymptomatic patients and from 2 to 38 days in symptomatic patients, with a similar mean duration in both groups (18.71 vs. 18.79 days; p=0.936). Conclusions: The estimated risk of SARS-CoV-2 infection was over 5 times higher in asymptomatic afebrile patients, and among laboratory markers, the inflammatory marker CRP was associated with a more severe COVID-19 outcome. Our study has several limitations that need to be acknowledged, including the small number of patients and the short follow-up period.

Author Biographies

  • Irina Mihaela ESANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine,
    Department of Medical Specialties (I)

  • Oana Irina GAVRIL, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine,
    Department of Medical Specialties (I)

  • Madalina Ioana ZOTA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine,
    Department of Medical Specialties (I)

  • A. DRUGESCU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine,
    Department of Medical Specialties (I)

  • Codrina ANCUTA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine,
    Department of Medical Specialties (II)

  • Ionela GROSU-CREANGA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Pharmacy,
    Department of Pharmaceutical Sciences (II)

  • R.S. GAVRIL, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine,
    Department of Medical Specialties (I)

References

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-513.
2. Yu P, Zhu J, Zhang Z, Han Y, Huang L. familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis 2020; 221(11): 1757-1761.
3. Bai Y, Yao L, Wei T et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020; 323(14): 1406-1407.
4. Hoehl S, Berger A, Kortenbusch M et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med 2020; 382(13): 1278-1280.
5. Chang D, Lin M, Wei Let al. Epidemiologic and clinicalv characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA 2020; 382(13) :1278-1280.
6. Wang JH, Kwon HJ, Jang YJ. Detection of parainfluenza virus 3 in turbinate epithelial cells of post viral olfactory dysfunction patients. Laryngoscope 2007; 117: 1445.
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
8. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
9. Guan WJ, Ni ZY, Hu Y, et al. China medical treatment expert group for, clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 58(4): 711- 712.
10. Li Tan QW, Zhang D, Ding Jet al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2020; 5(1): 33.
11. Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-768.
12. Guan W-j, Ni Z-y, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720.
13. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020; 295: 715-721.
14. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20: 425-434.
15. Inui S, Fujikawa A, Jitsu M, et al. Chest CT findings in cases from the cruise ship “Diamond Princess” with coronavirus disease 2019 (COVID-19). Radiol Cardiothorac Imaging 2020; 2(2) / doi: 10.1148/ryct.2020200110.

Additional Files

Published

2023-12-21

Issue

Section

INTERNAL MEDICINE - PEDIATRICS